Accumulating evidence for the role of the glycolytic activator PFKFB3 in angiogenesis and vessel barrier function further supports the notion of metabolism acting as a driving force in tumor blood vessel dysfunction [20, 24, 25]. This evidence concerns the gene PFKFB3 and neoplasm.